Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2020
発行: Global Markets Direct
ページ情報: 英文 2815 Pages
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer - Pipeline Review, H1 2020, provides an overview of the Kidney Cancer (Oncology) pipeline landscape.
Kidney cancer also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grows out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, and anemia, shortness of breath and bone pain. Treatment includes surgery, radiation therapy and chemotherapy.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Kidney Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Kidney Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 20, 162, 156, 2, 12, 101, 11 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 14, 8, 1, 16 and 1 molecules, respectively.
Kidney Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.